FACULTY RESEARCH

Faculty List

Antoni Ribas, M.D., Ph.D.

Work Email Address: aribas@mednet.ucla.edu

Office Phone Number: 310-794-4955

Work Phone Number: (310) 206-3928

Web-Profile

Work Address:
700 Tiverton Ave
BOX 951678
Los Angeles, CA 90095

Department / Division Affiliations
Chair, Melanoma Committee at SWOG
Director, Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC)
Co-Leader, Workforce Development
Professor of Medicine, Hematology-Oncology
Professor of Surgery, Surgical Oncology
Professor, Molecular & Medical Pharmacology
Member, CTSI, Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research, JCCC Cancer Molecular Imaging, JCCC Signal Transduction and Therapeutics Program Area, Molecular Pharmacology GPB Home Area, Molecular, Cellular & Integrative Physiology GPB Home Area


Publications
Giannoni Francesca, Hardee Cinnamon L, Wherley Jennifer, Gschweng Eric, Senadheera Shantha, Kaufman Michael L, Chan Rebecca, Bahner Ingrid, Gersuk Vivian, Wang Xiaoyan, Gjertson David, Baltimore David, Witte Owen N, Economou James S, Ribas Antoni, Kohn Donald B Allelic Exclusion and Peripheral Reconstitution by TCR Transgenic T Cells Arising From Transduced Human Hematopoietic Stem/Progenitor Cells. Molecular therapy : the journal of the American Society of Gene Therapy. 2013; 21(5): 1044-54.
Ribas Antoni, Wolchok Jedd D Combining cancer immunotherapy and targeted therapy. Current opinion in immunology. 2013; 25(2): 291-296.
Birkhäuser Frédéric D, Koya Richard C, Neufeld Caleb, Rampersaud Edward N, Lu Xuyang, Micewicz Ewa D, Chodon Thinle, Atefi Mohammad, Kroeger Nils, Chandramouli Gadisetti V R, Li Gang, Said Jonathan W, McBride William H, Kabbinavar Fairooz F, Ribas Antoni, Pantuck Allan J, Belldegrun Arie S, Riss Joseph Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(2): 102-11.
Gentilcore Giusy, Madonna Gabriele, Mozzillo Nicola, Ribas Antoni, Cossu Antonio, Palmieri Giuseppe, Ascierto Paolo A Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC cancer. 2013; 13(2): 17.
Klein Oliver, Ribas Antoni, Chmielowski Bartosz, Walker Grant, Clements Arthur, Long Georgina V, Kefford Richard F Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(12): e215-7.
Ribas Antoni, Hodi F Stephen, Callahan Margaret, Konto Cyril, Wolchok Jedd Hepatotoxicity with combination of vemurafenib and ipilimumab. The New England journal of medicine. 2013; 368(14): 1365-6.
Knight Deborah A, Ngiow Shin Foong, Li Ming, Parmenter Tiffany, Mok Stephen, Cass Ashley, Haynes Nicole M, Kinross Kathryn, Yagita Hideo, Koya Richard C, Graeber Thomas G, Ribas Antoni, McArthur Grant A, Smyth Mark J Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. The Journal of clinical investigation. 2013; 123(3): 1371-81.
Ma Chao, Cheung Ann F, Chodon Thinle, Koya Richard C, Wu Zhongqi, Ng Charles, Avramis Earl, Cochran Alistair J, Witte Owen N, Baltimore David, Chmielowski Bartosz, Economou James S, Comin-Anduix Begonya, Ribas Antoni, Heath James R Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer discovery. 2013; 3(4): 418-29.
Trunzer Kerstin, Pavlick Anna C, Schuchter Lynn, Gonzalez Rene, McArthur Grant A, Hutson Thomas E, Moschos Stergios J, Flaherty Keith T, Kim Kevin B, Weber Jeffrey S, Hersey Peter, Long Georgina V, Lawrence Donald, Ott Patrick A, Amaravadi Ravi K, Lewis Karl D, Puzanov Igor, Lo Roger S, Koehler Astrid, Kockx Mark, Spleiss Olivia, Schell-Steven Annette, Gilbert Houston N, Cockey Louise, Bollag Gideon, Lee Richard J, Joe Andrew K, Sosman Jeffrey A, Ribas Antoni Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(14): 1767-74.
Kim Kevin B, Kefford Richard, Pavlick Anna C, Infante Jeffrey R, Ribas Antoni, Sosman Jeffrey A, Fecher Leslie A, Millward Michael, McArthur Grant A, Hwu Patrick, Gonzalez Rene, Ott Patrick A, Long Georgina V, Gardner Olivia S, Ouellet Daniele, Xu Yanmei, DeMarini Douglas J, Le Ngocdiep T, Patel Kiran, Lewis Karl D Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(4): 482-9.
Ribas Antoni, Kefford Richard, Marshall Margaret A, Punt Cornelis J A, Haanen John B, Marmol Maribel, Garbe Claus, Gogas Helen, Schachter Jacob, Linette Gerald, Lorigan Paul, Kendra Kari L, Maio Michele, Trefzer Uwe, Smylie Michael, McArthur Grant A, Dreno Brigitte, Nathan Paul D, Mackiewicz Jacek, Kirkwood John M, Gomez-Navarro Jesus, Huang Bo, Pavlov Dmitri, Hauschild Axel Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(5): 616-22.
Hou Shuang, Zhao Libo, Shen Qinglin, Yu Juehua, Ng Charles, Kong Xiangju, Wu Dongxia, Song Min, Shi Xiaohong, Xu Xiaochun, OuYang Wei-Han, He Rongxian, Zhao Xing-Zhong, Lee Tom, Brunicardi F Charles, Garcia Mitch André, Ribas Antoni, Lo Roger S, Tseng Hsian-Rong Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angewandte Chemie (International ed. in English). 2013; 52(12): 3379-83.
Anker Christopher J, Ribas Antoni, Grossmann Allie H, Chen Xinjian, Narra Krishna K, Akerley Wallace, Andtbacka Robert H I, Noyes Robert Dirk, Shrieve Dennis C, Grossmann Kenneth F Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(14): .
McArthur Grant A, Ribas Antoni Targeting oncogenic drivers and the immune system in melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(4): 499-506.
von Euw Erika, Atefi Mohammad, Attar Narsis, Chu Connie, Zachariah Sybil, Burgess Barry L, Mok Stephen, Ng Charles, Wong Deborah Jl, Chmielowski Bartosz, Lichter David I, Koya Richard C, McCannel Tara A, Izmailova Elena, Ribas Antoni Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Molecular cancer. 2012; 11(3): 22.
Koya Richard C, Mok Stephen, Otte Nicholas, Blacketor Kevin J, Comin-Anduix Begonya, Tumeh Paul C, Minasyan Aspram, Graham Nicholas A, Graeber Thomas G, Chodon Thinle, Ribas Antoni BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer research. 2012; 72(16): 3928-37.
Dahlman Kimberly Brown, Xia Junfeng, Hutchinson Katherine, Ng Charles, Hucks Donald, Jia Peilin, Atefi Mohammad, Su Zengliu, Branch Suzanne, Lyle Pamela L, Hicks Donna J, Bozon Viviana, Glaspy John A, Rosen Neal, Solit David B, Netterville James L, Vnencak-Jones Cindy L, Sosman Jeffrey A, Ribas Antoni, Zhao Zhongming, Pao William BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors. Cancer discovery. 2012; 2(9): 791-797.
Ribas Antoni, Tumeh Paul C Cancer therapy: Tumours switch to resist. Nature. 2012; 490(7420): 347-8.
Ascierto Paolo A, Grimaldi Antonio M, Curti Brendan, Faries Mark B, Ferrone Soldano, Flaherty Keith, Fox Bernard A, Gajewski Thomas F, Gershenwald Jeffrey E, Gogas Helen, Grossmann Kenneth, Hauschild Axel, Hodi F Stephen, Kefford Richard, Kirkwood John M, Leachmann Sancy, Maio Michele, Marais Richard, Palmieri Giuseppe, Morton Donald L, Ribas Antoni, Stroncek David F, Stewart Rodney, Wang Ena, Mozzillo Nicola, Marincola Franco M Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011". Journal of translational medicine. 2012; 10(7408): 83.
Graham Nicholas A, Tahmasian Martik, Kohli Bitika, Komisopoulou Evangelia, Zhu Maggie, Vivanco Igor, Teitell Michael A, Wu Hong, Ribas Antoni, Lo Roger S, Mellinghoff Ingo K, Mischel Paul S, Graeber Thomas G Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Molecular systems biology. 2012; 8(26): 589.
Ribas Antoni Immunoediting the cancer genome--a new approach for personalized cancer therapy?. Pigment cell & melanoma research. 2012; 25(3): 297-8.
Narayan Rupa, Nguyen Hong, Bentow Jason J, Moy Lauren, Lee Diana K, Greger Stephanie, Haskell Jacquelyn, Vanchinathan Veena, Chang Pei-Lin, Tsui Shanli, Konishi Tamiko, Comin-Anduix Begonya, Dauphine Christine, Vargas Hernan I, Economou James S, Ribas Antoni, Bruhn Kevin W, Craft Noah Immunomodulation by imiquimod in patients with high-risk primary melanoma. The Journal of investigative dermatology. 2012; 132(1): 163-9.
McArthur Grant A, Puzanov Igor, Amaravadi Ravi, Ribas Antoni, Chapman Paul, Kim Kevin B, Sosman Jeffrey A, Lee Richard J, Nolop Keith, Flaherty Keith T, Callahan Jason, Hicks Rodney J Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30(14): 1628-34.
Smalley Keiran S M, Aplin Andrew E, Flaherty Keith T, Hoeller Christoph, Bosserhoff Anja K, Haass Nikolas K, Bosenberg Marcus, Ribas Antoni, Barnhill Raymond, Kudchadkar Ragini, Messina Jane L Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment cell & melanoma research. 2012; 25(1): E1-11.
Shi Hubing, Moriceau Gatien, Kong Xiangju, Lee Mi-Kyung, Lee Hane, Koya Richard C, Ng Charles, Chodon Thinle, Scolyer Richard A, Dahlman Kimberly B, Sosman Jeffrey A, Kefford Richard F, Long Georgina V, Nelson Stanley F, Ribas Antoni, Lo Roger S Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature communications. 2012; 3: 724.
Ribas Antoni, Hersey Peter, Middleton Mark R, Gogas Helen, Flaherty Keith T, Sondak Vernon K, Kirkwood John M New challenges in endpoints for drug development in advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(2): 336-41.
Bhatia Shailender, Moon James, Margolin Kim A, Weber Jeffrey S, Lao Christopher D, Othus Megan, Aparicio Ana M, Ribas Antoni, Sondak Vernon K Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PloS one. 2012; 7(11): e48787.
Shi Hubing, Moriceau Gatien, Kong Xiangju, Koya Richard C, Nazarian Ramin, Pupo Gulietta M, Bacchiocchi Antonella, Dahlman Kimberly B, Chmielowski Bartosz, Sosman Jeffrey A, Halaban Ruth, Kefford Richard F, Long Georgina V, Ribas Antoni, Lo Roger S Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer discovery. 2012; 2(5): 414-24.
Ribas Antoni Q&A: Antoni Ribas on immunotherapy progress. Cancer discovery. 2012; 2(4): 293.
Su Fei, Viros Amaya, Milagre Carla, Trunzer Kerstin, Bollag Gideon, Spleiss Olivia, Reis-Filho Jorge S, Kong Xiangju, Koya Richard C, Flaherty Keith T, Chapman Paul B, Kim Min Jung, Hayward Robert, Martin Matthew, Yang Hong, Wang Qiongqing, Hilton Holly, Hang Julie S, Noe Johannes, Lambros Maryou, Geyer Felipe, Dhomen Nathalie, Niculescu-Duvaz Ion, Zambon Alfonso, Niculescu-Duvaz Dan, Preece Natasha, Robert Lídia, Otte Nicholas J, Mok Stephen, Kee Damien, Ma Yan, Zhang Chao, Habets Gaston, Burton Elizabeth A, Wong Bernice, Nguyen Hoa, Kockx Mark, Andries Luc, Lestini Brian, Nolop Keith B, Lee Richard J, Joe Andrew K, Troy James L, Gonzalez Rene, Hutson Thomas E, Puzanov Igor, Chmielowski Bartosz, Springer Caroline J, McArthur Grant A, Sosman Jeffrey A, Lo Roger S, Ribas Antoni, Marais Richard RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. The New England journal of medicine. 2012; 366(3): 207-15.
Ribas Antoni, Chesney Jason A, Gordon Michael S, Abernethy Amy P, Logan Theodore F, Lawson David H, Chmielowksi Bartosz, Glaspy John A, Lewis Karl, Huang Bo, Wang Erjian, Hsyu Poe-Hirr, Gomez-Navarro Jesus, Gerhardt Diana, Marshall Margaret A, Gonzalez Rene Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. Journal of translational medicine. 2012; 10(2): 236.
Sosman Jeffrey A, Kim Kevin B, Schuchter Lynn, Gonzalez Rene, Pavlick Anna C, Weber Jeffrey S, McArthur Grant A, Hutson Thomas E, Moschos Stergios J, Flaherty Keith T, Hersey Peter, Kefford Richard, Lawrence Donald, Puzanov Igor, Lewis Karl D, Amaravadi Ravi K, Chmielowski Bartosz, Lawrence H Jeffrey, Shyr Yu, Ye Fei, Li Jiang, Nolop Keith B, Lee Richard J, Joe Andrew K, Ribas Antoni Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England journal of medicine. 2012; 366(8): 707-14.
Paraiso Kim H T, Haarberg H Eirik, Wood Elizabeth, Rebecca Vito W, Chen Y Ann, Xiang Yun, Ribas Antoni, Lo Roger S, Weber Jeffrey S, Sondak Vernon K, John Jobin K, Sarnaik Amod A, Koomen John M, Smalley Keiran S M The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(9): 2502-14.
Ribas Antoni Tumor immunotherapy directed at PD-1. The New England journal of medicine. 2012; 366(26): 2517-9.
Straussman Ravid, Morikawa Teppei, Shee Kevin, Barzily-Rokni Michal, Qian Zhi Rong, Du Jinyan, Davis Ashli, Mongare Margaret M, Gould Joshua, Frederick Dennie T, Cooper Zachary A, Chapman Paul B, Solit David B, Ribas Antoni, Lo Roger S, Flaherty Keith T, Ogino Shuji, Wargo Jennifer A, Golub Todd R Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487(7408): 500-4.
Wilson Timothy R, Fridlyand Jane, Yan Yibing, Penuel Elicia, Burton Luciana, Chan Emily, Peng Jing, Lin Eva, Wang Yulei, Sosman Jeff, Ribas Antoni, Li Jiang, Moffat John, Sutherlin Daniel P, Koeppen Hartmut, Merchant Mark, Neve Richard, Settleman Jeff Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012; 487(7408): 505-9.
Vu Nam T, Yu Zeta T F, Comin-Anduix Begonya, Søndergaard Jonas N, Silverman Robert W, Chang Canny Y N, Ribas Antoni, Tseng Hsian-Rong, Chatziioannou Arion F A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011; 52(5): 815-21.
Ma Chao, Fan Rong, Ahmad Habib, Shi Qihui, Comin-Anduix Begonya, Chodon Thinle, Koya Richard C, Liu Chao-Chao, Kwong Gabriel A, Radu Caius G, Ribas Antoni, Heath James R A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nature medicine. 2011; 17(6): 738-43.
Hwang Tae-Ho, Moon Anne, Burke James, Ribas Antoni, Stephenson Joe, Breitbach Caroline J, Daneshmand Manijeh, De Silva Naomi, Parato Kelley, Diallo Jean-Simon, Lee Yeon-Sook, Liu Ta-Chiang, Bell John C, Kirn David H A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Molecular therapy : the journal of the American Society of Gene Therapy. 2011; 19(10): 1913-22.
Ascierto Paolo A, Marincola Francesco M, Ribas Antoni Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. Journal of translational medicine. 2011; 9(1): 196.
Vatakis Dimitrios N, Koya Richard C, Nixon Christopher C, Wei Liu, Kim Sohn G, Avancena Patricia, Bristol Gregory, Baltimore David, Kohn Donald B, Ribas Antoni, Radu Caius G, Galic Zoran, Zack Jerome A Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(51): E1408-16.
Ribas Antoni, Flaherty Keith T BRAF targeted therapy changes the treatment paradigm in melanoma. Nature reviews. Clinical oncology. 2011; 8(7): 426-33.
Huang Rong Rong, Jalil Jason, Economou James S, Chmielowski Bartosz, Koya Richard C, Mok Stephen, Sazegar Hooman, Seja Elizabeth, Villanueva Arturo, Gomez-Navarro Jesus, Glaspy John A, Cochran Alistair J, Ribas Antoni CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011; 17(12): 4101-9.
Niehr Franziska, von Euw Erika, Attar Narsis, Guo Deliang, Matsunaga Doug, Sazegar Hooman, Ng Charles, Glaspy John A, Recio Juan A, Lo Roger S, Mischel Paul S, Comin-Anduix Begonya, Ribas Antoni Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. Journal of translational medicine. 2011; 9(6): 76.
Shi Hubing, Kong Xiangju, Ribas Antoni, Lo Roger S Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer research. 2011; 71(15): 5067-74.
Konkankit Veerauo V, Kim Won, Koya Richard C, Eskin Ascia, Dam Mai-Anh, Nelson Stanley, Ribas Antoni, Liau Linda M, Prins Robert M Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. Journal of translational medicine. 2011; 9(1): 192.
Fox Bernard A, Schendel Dolores J, Butterfield Lisa H, Aamdal Steinar, Allison James P, Ascierto Paolo Antonio, Atkins Michael B, Bartunkova Jirina, Bergmann Lothar, Berinstein Neil, Bonorino Cristina C, Borden Ernest, Bramson Jonathan L, Britten Cedrik M, Cao Xuetao, Carson William E, Chang Alfred E, Characiejus Dainius, Choudhury A Raja, Coukos George, de Gruijl Tanja, Dillman Robert O, Dolstra Harry, Dranoff Glenn, Durrant Lindy G, Finke James H, Galon Jerome, Gollob Jared A, Gouttefangeas Cécile, Grizzi Fabio, Guida Michele, Håkansson Leif, Hege Kristen, Herberman Ronald B, Hodi F Stephen, Hoos Axel, Huber Christoph, Hwu Patrick, Imai Kohzoh, Jaffee Elizabeth M, Janetzki Sylvia, June Carl H, Kalinski Pawel, Kaufman Howard L, Kawakami Koji, Kawakami Yutaka, Keilholtz Ulrich, Khleif Samir N, Kiessling Rolf, Kotlan Beatrix, Kroemer Guido, Lapointe Rejean, Levitsky Hyam I, Lotze Michael T, Maccalli Cristina, Maio Michele, Marschner Jens-Peter, Mastrangelo Michael J, Masucci Giuseppe, Melero Ignacio, Melief Cornelius, Murphy William J, Nelson Brad, Nicolini Andrea, Nishimura Michael I, Odunsi Kunle, Ohashi Pamela S, O'Donnell-Tormey Jill, Old Lloyd J, Ottensmeier Christian, Papamichail Michael, Parmiani Giorgio, Pawelec Graham, Proietti Enrico, Qin Shukui, Rees Robert, Ribas Antoni, Ridolfi Ruggero, Ritter Gerd, Rivoltini Licia, Romero Pedro J, Salem Mohamed L, Scheper Rik J, Seliger Barbara, Sharma Padmanee, Shiku Hiroshi, Singh-Jasuja Harpreet, Song Wenru, Straten Per Thor, Tahara Hideaki, Tian Zhigang, van Der Burg Sjoerd H, von Hoegen Paul, Wang Ena, Welters Marij Jp, Winter Hauke, Withington Tara, Wolchok Jedd D, Xiao Weihua, Zitvogel Laurence, Zwierzina Heinz, Marincola Francesco M, Gajewski Thomas F, Wigginton Jon M, Disis Mary L Defining the critical hurdles in cancer immunotherapy. Journal of translational medicine. 2011; 9(1): 214.
Ascierto Paolo A, De Maio Eleonora, Bertuzzi Stefano, Palmieri Giuseppe, Halaban Ruth, Hendrix Mary, Kashani-sabet Mohamed, Ferrone Soldano, Wang Ena, Cochran Alistair, Rivoltini Licia, Lee Peter P, Fox Bernard A, Kirkwood John M, Ullmann Claudio Dansky, Lehmann Frederic F, Sznol Mario, Schwartzentruber Douglas J, Maio Michele, Flaherty Keith, Galon Jerome, Ribas Antoni, Yang James, Stroncek David F, Mozzillo Nicola, Marincola Franco M Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". Journal of translational medicine. 2011; 9(7): 32.
Chapman Paul B, Hauschild Axel, Robert Caroline, Haanen John B, Ascierto Paolo, Larkin James, Dummer Reinhard, Garbe Claus, Testori Alessandro, Maio Michele, Hogg David, Lorigan Paul, Lebbe Celeste, Jouary Thomas, Schadendorf Dirk, Ribas Antoni, O'Day Steven J, Sosman Jeffrey A, Kirkwood John M, Eggermont Alexander M M, Dreno Brigitte, Nolop Keith, Li Jiang, Nelson Betty, Hou Jeannie, Lee Richard J, Flaherty Keith T, McArthur Grant A, McArthur Grant A Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011; 364(26): 2507-16.
Ribas Antoni, Weber Jeffrey S, Chmielowski Bartosz, Comin-Anduix Begonya, Lu David, Douek Michael, Ragavendra Nagesh, Raman Steve, Seja Elizabeth, Rosario Darlene, Miles Sabrina, Diamond David C, Qiu Zhiyong, Obrocea Mihail, Bot Adrian Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011; 17(9): 2987-96.
Paraiso Kim H T, Xiang Yun, Rebecca Vito W, Abel Ethan V, Chen Y Ann, Munko A Cecilia, Wood Elizabeth, Fedorenko Inna V, Sondak Vernon K, Anderson Alexander R A, Ribas Antoni, Palma Maurizia Dalla, Nathanson Katherine L, Koomen John M, Messina Jane L, Smalley Keiran S M PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer research. 2011; 71(7): 2750-60.
Poulikakos Poulikos I, Persaud Yogindra, Janakiraman Manickam, Kong Xiangju, Ng Charles, Moriceau Gatien, Shi Hubing, Atefi Mohammad, Titz Bjoern, Gabay May Tal, Salton Maayan, Dahlman Kimberly B, Tadi Madhavi, Wargo Jennifer A, Flaherty Keith T, Kelley Mark C, Misteli Tom, Chapman Paul B, Sosman Jeffrey A, Graeber Thomas G, Ribas Antoni, Lo Roger S, Rosen Neal, Solit David B RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480(7377): 387-90.
Atefi Mohammad, von Euw Erika, Attar Narsis, Ng Charles, Chu Connie, Guo Deliang, Nazarian Ramin, Chmielowski Bartosz, Glaspy John A, Comin-Anduix Begonya, Mischel Paul S, Lo Roger S, Ribas Antoni Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PloS one. 2011; 6(12): e28973.
Zuckerman Jonathan E, Hsueh Teli, Koya Richard C, Davis Mark E, Ribas Antoni siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. The Journal of investigative dermatology. 2011; 131(2): 453-60.
Weber Jeffrey S, Samlowski Wolfram E, Gonzalez Rene, Ribas Antoni, Stephenson Joe, O'Day Steven, Sato Takami, Dorr Robert, Grenier Kathryn, Hersh Evan A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010; 116(15): 3683-91.
Hersh Evan M, O'Day Steven J, Ribas Antoni, Samlowski Wolfram E, Gordon Michael S, Shechter Deganit E, Clawson Alicia A, Gonzalez Rene A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010; 116(1): 155-63.
Ribas Antoni, Koya Richard C Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling. Future oncology (London, England). 2010; 6(11): 1671-3.
Kalbasi Anusha, Fonsatti Ester, Natali Pier Giorgio, Altomonte Maresa, Bertocci Erica, Cutaia Ornella, Calabrò Luana, Chiou Michael, Tap William, Chmielowski Bartosz, Maio Michele, Ribas Antoni CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(8): 810-6.
Ribas Antoni Clinical development of the anti-CTLA-4 antibody tremelimumab. Seminars in oncology. 2010; 37(5): 450-4.
Bollag Gideon, Hirth Peter, Tsai James, Zhang Jiazhong, Ibrahim Prabha N, Cho Hanna, Spevak Wayne, Zhang Chao, Zhang Ying, Habets Gaston, Burton Elizabeth A, Wong Bernice, Tsang Garson, West Brian L, Powell Ben, Shellooe Rafe, Marimuthu Adhirai, Nguyen Hoa, Zhang Kam Y J, Artis Dean R, Schlessinger Joseph, Su Fei, Higgins Brian, Iyer Raman, D'Andrea Kurt, Koehler Astrid, Stumm Michael, Lin Paul S, Lee Richard J, Grippo Joseph, Puzanov Igor, Kim Kevin B, Ribas Antoni, McArthur Grant A, Sosman Jeffrey A, Chapman Paul B, Flaherty Keith T, Xu Xiaowei, Nathanson Katherine L, Nolop Keith Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010; 467(7315): 596-9.
Agarwala Sanjiv S, Ribas Antoni Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(6): 557-69.
Søndergaard Jonas N, Nazarian Ramin, Wang Qi, Guo Deliang, Hsueh Teli, Mok Stephen, Sazegar Hooman, MacConaill Laura E, Barretina Jordi G, Kehoe Sarah M, Attar Narsis, von Euw Erika, Zuckerman Jonathan E, Chmielowski Bartosz, Comin-Anduix Begoña, Koya Richard C, Mischel Paul S, Lo Roger S, Ribas Antoni Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. Journal of translational medicine. 2010; 8(6): 39.
Davis Mark E, Zuckerman Jonathan E, Choi Chung Hang J, Seligson David, Tolcher Anthony, Alabi Christopher A, Yen Yun, Heidel Jeremy D, Ribas Antoni Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464(7291): 1067-70.
Brusko Todd M, Koya Richard C, Zhu Shirley, Lee Michael R, Putnam Amy L, McClymont Stephanie A, Nishimura Michael I, Han Shuhong, Chang Lung-Ji, Atkinson Mark A, Ribas Antoni, Bluestone Jeffrey A Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PloS one. 2010; 5(7): e11726.
Ribas Antoni, Benz Matthias R, Allen-Auerbach Martin S, Radu Caius, Chmielowski Bartosz, Seja Elizabeth, Williams John L, Gomez-Navarro Jesus, McCarthy Timothy, Czernin Johannes Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010; 51(3): 340-6.
Schaue Dörthe, Koya Richard C, Liao Yu-Pei, Ribas Antoni, McBride William H Immune rejection in a humanized model of murine prostate cancer. Anticancer research. 2010; 30(2): 409-14.
Flaherty Keith T, Puzanov Igor, Kim Kevin B, Ribas Antoni, McArthur Grant A, Sosman Jeffrey A, O'Dwyer Peter J, Lee Richard J, Grippo Joseph F, Nolop Keith, Chapman Paul B Inhibition of mutated, activated BRAF in metastatic melanoma. The New England journal of medicine. 2010; 363(9): 809-19.
Koya Richard C, Mok Stephen, Comin-Anduix Begoña, Chodon Thinle, Radu Caius G, Nishimura Michael I, Witte Owen N, Ribas Antoni Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(32): 14286-91.
Ray Swagatam, Chhabra Arvind, Chakraborty Nitya G, Hegde Upendra, Dorsky David I, Chodon Thinle, von Euw Erika, Comin-Anduix Begonya, Koya Richard C, Ribas Antoni, Economou James S, Rosenberg Steven A, Mukherji Bijay, Mukherji Bijay MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clinical immunology (Orlando, Fla.). 2010; 136(3): 338-47.
Agarwala Sanjiv S, di Pietro Alessandra, Flaherty Keith T, Garbe Claus, Grob Jean-Jacques, Kashani-Sabet Mohammed, Kirkwood John M, Leachman Sancy, Messina Jane, O'Day Steven, Ribas Antoni, Sondak Vernon Meeting report from the Third Global Workshop on Melanoma. Pigment cell & melanoma research. 2010; 23(5): e1-7.
Nazarian Ramin, Shi Hubing, Wang Qi, Kong Xiangju, Koya Richard C, Lee Hane, Chen Zugen, Lee Mi-Kyung, Attar Narsis, Sazegar Hooman, Chodon Thinle, Nelson Stanley F, McArthur Grant, Sosman Jeffrey A, Ribas Antoni, Lo Roger S Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326): 973-7.
Comin-Anduix Begoña, Sazegar Hooman, Chodon Thinle, Matsunaga Douglas, Jalil Jason, von Euw Erika, Escuin-Ordinas Helena, Balderas Robert, Chmielowski Bartosz, Gomez-Navarro Jesus, Koya Richard C, Ribas Antoni Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PloS one. 2010; 5(9): e12711.
Ribas Antoni, Camacho Luis H, Lee Sun Min, Hersh Evan M, Brown Charles K, Richards Jon M, Rodriguez Maria Jovie, Prieto Victor G, Glaspy John A, Oseguera Denise K, Hernandez Jackie, Villanueva Arturo, Chmielowski Bartosz, Mitsky Peggie, Bercovici Nadège, Wasserman Ernesto, Landais Didier, Ross Merrick I Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. Journal of translational medicine. 2010; 8(5): 89.
Baltimore David, Witte Owen N, Yang Lili, Economou James, Ribas Antoni Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma. Pigment cell & melanoma research. 2010; 23(2): 288-9.
Tumeh Paul C, Koya Richard C, Chodon Thinle, Graham Nicholas A, Graeber Thomas G, Comin-Anduix Begoña, Ribas Antoni The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(8): 759-68.
Comin-Anduix Begoña, Chodon Thinle, Sazegar Hooman, Matsunaga Douglas, Mock Stephen, Jalil Jason, Escuin-Ordinas Helena, Chmielowski Bartosz, Koya Richard C, Ribas Antoni The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010; 16(24): 6040-8.
von Euw Erika, Chodon Thinle, Attar Narsis, Jalil Jason, Koya Richard C, Comin-Anduix Begonya, Ribas Antoni CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. Journal of translational medicine. 2009; 7(6): 35.
Ribas Antoni, Comin-Anduix Begoña, Chmielowski Bartosz, Jalil Jason, de la Rocha Pilar, McCannel Tara A, Ochoa Maria Teresa, Seja Elizabeth, Villanueva Arturo, Oseguera Denise K, Straatsma Bradley R, Cochran Alistair J, Glaspy John A, Hui Liu, Marincola Francesco M, Wang Ena, Economou James S, Gomez-Navarro Jesus Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(19): 6267-76.
Ribas Antoni, Chmielowski Bartosz, Glaspy John A Do we need a different set of response assessment criteria for tumor immunotherapy?. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(23): 7116-8.
Bellmunt Joaquim, Ribas Antoni Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. European urology. 2009; 55(6): 1342-3.
Tahara Hideaki, Sato Marimo, Thurin Magdalena, Wang Ena, Butterfield Lisa H, Disis Mary L, Fox Bernard A, Lee Peter P, Khleif Samir N, Wigginton Jon M, Ambs Stefan, Akutsu Yasunori, Chaussabel Damien, Doki Yuichiro, Eremin Oleg, Fridman Wolf Hervé, Hirohashi Yoshihiko, Imai Kohzoh, Jacobson James, Jinushi Masahisa, Kanamoto Akira, Kashani-Sabet Mohammed, Kato Kazunori, Kawakami Yutaka, Kirkwood John M, Kleen Thomas O, Lehmann Paul V, Liotta Lance, Lotze Michael T, Maio Michele, Malyguine Anatoli, Masucci Giuseppe, Matsubara Hisahiro, Mayrand-Chung Shawmarie, Nakamura Kiminori, Nishikawa Hiroyoshi, Palucka A Karolina, Petricoin Emanuel F, Pos Zoltan, Ribas Antoni, Rivoltini Licia, Sato Noriyuki, Shiku Hiroshi, Slingluff Craig L, Streicher Howard, Stroncek David F, Takeuchi Hiroya, Toyota Minoru, Wada Hisashi, Wu Xifeng, Wulfkuhle Julia, Yaguchi Tomonori, Zeskind Benjamin, Zhao Yingdong, Zocca Mai-Britt, Marincola Francesco M Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. Journal of translational medicine. 2009; 7(18): 45.
Vo Dan D, Prins Robert M, Begley Jonathan L, Donahue Timothy R, Morris Lilah F, Bruhn Kevin W, de la Rocha Pilar, Yang Meng-Yin, Mok Stephen, Garban Hermes J, Craft Noah, Economou James S, Marincola Francesco M, Wang Ena, Ribas Antoni Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer research. 2009; 69(22): 8693-9.
Curtin James F, Liu Naiyou, Candolfi Marianela, Xiong Weidong, Assi Hikmat, Yagiz Kader, Edwards Matthew R, Michelsen Kathrin S, Kroeger Kurt M, Liu Chunyan, Muhammad A K M Ghulam, Clark Mary C, Arditi Moshe, Comin-Anduix Begonya, Ribas Antoni, Lowenstein Pedro R, Castro Maria G HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS medicine. 2009; 6(1): e10.
Begley Jonathan, Vo Dan D, Morris Lilah F, Bruhn Kevin W, Prins Robert M, Mok Stephen, Koya Richard C, Garban Hermes J, Comin-Anduix Begonya, Craft Noah, Ribas Antoni Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer immunology, immunotherapy : CII. 2009; 58(5): 699-708.
Glaspy John, Ribas Antoni, Chmielowski Bartosz Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27(18): 2896-7.
Ribas Antoni, Comin-Anduix Begoña, Economou James S, Donahue Timothy R, de la Rocha Pilar, Morris Lilah F, Jalil Jason, Dissette Vivian B, Shintaku Itsushi Peter, Glaspy John A, Gomez-Navarro Jesus, Cochran Alistair J Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(1): 390-9.
Agarwala Sanjiv S, Becker Jurgen C, Eggermont Alexander M, Flaherty Keith T, Garbe Claus, Goldstein Alisa M, Halpern Allan, Kashani-Sabet Mohammed, Hauschild Axel, Kirkwood John M, Leachman Sancy, Lorigan Paul, McMahon Martin, Messina Jane, Ribas Antoni, Samlowski Wolfram E, Schadendorf Dirk, Sondak Vernon K Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment cell & melanoma research. 2009; 22(5): 532-43.
Kwong Gabriel A, Radu Caius G, Hwang Kiwook, Shu Chengyi J, Ma Chao, Koya Richard C, Comin-Anduix Begonya, Hadrup Sine Reker, Bailey Ryan C, Witte Owen N, Schumacher Ton N, Ribas Antoni, Heath James R Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. Journal of the American Chemical Society. 2009; 131(28): 9695-703.
Ray Swagatam, Chhabra Arvind, Mehrotra Shikhar, Chakraborty Nitya G, Ribas Antoni, Economou James, Mukherji Bijay Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clinics in dermatology. 2009; 27(6): 603-13.
Ribas Antoni, Kirkwood John M, Atkins Michael B, Whiteside Theresa L, Gooding William, Kovar Andreas, Gillies Stephen D, Kashala Oscar, Morse Michael A Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. Journal of translational medicine. 2009; 7(5): 68.
Camacho Luis H, Antonia Scott, Sosman Jeffrey, Kirkwood John M, Gajewski Thomas F, Redman Bruce, Pavlov Dmitri, Bulanhagui Cecile, Bozon Viviana A, Gomez-Navarro Jesus, Ribas Antoni Phase I/II trial of tremelimumab in patients with metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27(7): 1075-81.
Shu Chengyi J, Radu Caius G, Shelly Stephanie M, Vo Dan D, Prins Robert, Ribas Antoni, Phelps Michael E, Witte Owen N Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. International immunology. 2009; 21(2): 155-65.
Butterfield Lisa H, Disis Mary L, Fox Bernard A, Lee Peter P, Khleif Samir N, Thurin Magdalena, Trinchieri Giorgio, Wang Ena, Wigginton Jon, Chaussabel Damien, Coukos George, Dhodapkar Madhav, HÃ¥kansson Leif, Janetzki Sylvia, Kleen Thomas O, Kirkwood John M, Maccalli Cristina, Maecker Holden, Maio Michele, Malyguine Anatoli, Masucci Giuseppe, Palucka A Karolina, Potter Douglas M, Ribas Antoni, Rivoltini Licia, Schendel Dolores, Seliger Barbara, Selvan Senthamil, Slingluff Craig L, Stroncek David F, Streicher Howard, Wu Xifeng, Zeskind Benjamin, Zhao Yingdong, Zocca Mai-Britt, Zwierzina Heinz, Marincola Francesco M A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of translational medicine. 2008; 6(1): 81.
Butterfield Lisa H, Comin-Anduix Begonya, Vujanovic Lazar, Lee Yohan, Dissette Vivian B, Yang Jin-Quan, Vu Hong T, Seja Elizabeth, Oseguera Denise K, Potter Douglas M, Glaspy John A, Economou James S, Ribas Antoni Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(3): 294-309.
Prins Robert M, Shu Chengyi J, Radu Caius G, Vo Dan D, Khan-Farooqi Haumith, Soto Horacio, Yang Meng-Yin, Lin Muh-Shi, Shelly Stephanie, Witte Owen N, Ribas Antoni, Liau Linda M Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer immunology, immunotherapy : CII. 2008; 57(9): 1279-89.
Chhabra Arvind, Yang Lili, Wang Pin, Comin-Anduix Begoña, Das Raja, Chakraborty Nitya G, Ray Swagatam, Mehrotra Shikhar, Yang Haiguang, Hardee Cinnamon L, Hollis Roger, Dorsky David I, Koya Richard, Kohn Donald B, Ribas Antoni, Economou James S, Baltimore David, Mukherji Bijay CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(2): 1063-70.
Comin-Anduix Begoña, Lee Yohan, Jalil Jason, Algazi Alain, de la Rocha Pilar, Camacho Luis H, Bozon Viviana A, Bulanhagui Cecile A, Seja Elisabeth, Villanueva Arturo, Straatsma Bradley R, Gualberto Antonio, Economou James S, Glaspy John A, Gomez-Navarro Jesus, Ribas Antoni Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. Journal of translational medicine. 2008; 6(6): 22.
Ribas Antoni Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). The oncologist. 2008; 13 Suppl 4(3): 10-5.
Tumeh Paul C, Radu Caius G, Ribas Antoni PET imaging of cancer immunotherapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2008; 49(6): 865-8.
Schaue Dörthe, Comin-Anduix Begonya, Ribas Antoni, Zhang Li, Goodglick Lee, Sayre James W, Debucquoy Annelies, Haustermans Karin, McBride William H T-cell responses to survivin in cancer patients undergoing radiation therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(15): 4883-90.
Begley Jonathan, Ribas Antoni Targeted therapies to improve tumor immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(14): 4385-91.
Ribas Antoni Anti-CTLA4 Antibody Clinical Trials in Melanoma. Update on cancer therapeutics. 2007; 2(3): 133-139.
Koya Richard C, Kimura Takahiro, Ribas Antoni, Rozengurt Nora, Lawson Gregory W, Faure-Kumar Emmanuelle, Wang He-jing, Herschman Harvey, Kasahara Noriyuki, Stripecke Renata Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Molecular therapy : the journal of the American Society of Gene Therapy. 2007; 15(5): 971-80.
Klatte Tobias, Rao Jian Yu, Ribas Antoni, Pantuck Allan J Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. Urology. 2007; 69(5): 982.e7-9.
Butterfield Lisa H, Ribas Antoni, Potter Douglas M, Economou James S Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer immunology, immunotherapy : CII. 2007; 56(12): 1931-43.
Straatsma Bradley R, Nusinowitz Steven, Young Tara A, Gordon Lynn K, Chun Melissa W, Rosen Colleen, Seja Elisabeth, Economou James S, Glaspy John A, Bozon Viviana, Gomez-Navarro Jesus, Ribas Antoni Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. American journal of ophthalmology. 2007; 143(6): 958-969.
Morris Lilah F, Ribas Antoni Therapeutic cancer vaccines. Surgical oncology clinics of North America. 2007; 16(4): 819-31, ix.
Ribas Antoni, Hanson Douglas C, Noe Dennis A, Millham Robert, Guyot Deborah J, Bernstein Steven H, Canniff Paul C, Sharma Amarnath, Gomez-Navarro Jesus Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. The oncologist. 2007; 12(7): 873-83.
Butterfield Lisa H, Ribas Antoni, Dissette Vivian B, Lee Yohan, Yang Jin Quan, De la Rocha Pilar, Duran Sonia D, Hernandez Jackie, Seja Elisabeth, Potter Douglas M, McBride William H, Finn Richard, Glaspy John A, Economou James S A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(9): 2817-25.
Dela Cruz Jay Soriano, Trinh Kamh Ryan, Chen Hsiao Wen, Ribas Antoni, Morrison Sherie L, Penichet Manuel L Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Molecular immunology. 2006; 43(6): 667-76.
Ribas Antoni, Vo Dan D, Weeks David L, Comin-Anduix Begoña, Schumacher Lana Y, Garban Hermes J, McLean Colin, Yang Jinquan, Dissette Vivian B, Peraza Pedro, Owens Sharla K, McBride William H, Glaspy John A, Economou James S Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer immunology, immunotherapy : CII. 2006; 55(6): 663-71.
Comin-Anduix Begoña, Gualberto Antonio, Glaspy John A, Seja Elisabeth, Ontiveros Maribel, Reardon Deborah L, Renteria Roberto, Englahner Brigitte, Economou James S, Gomez-Navarro Jesus, Ribas Antoni Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(1): 107-16.
Schumacher Lana Y, Vo Dan D, Garban Hermes J, Comin-Anduix Begoña, Owens Sharla K, Dissette Vivian B, Glaspy John A, McBride William H, Bonavida Benjamin, Economou James S, Ribas Antoni Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). Journal of immunology (Baltimore, Md. : 1950). 2006; 176(8): 4757-65.
Prins Robert M, Vo Dan D, Khan-Farooqi Haumith, Yang Meng-Yin, Soto Horacio, Economou James S, Liau Linda M, Ribas Antoni NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. Journal of immunology (Baltimore, Md. : 1950). 2006; 177(12): 8448-55.
Ribas Antoni Update on immunotherapy for melanoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2006; 4(7): 687-94.
Ribas Antoni, Camacho Luis H, Lopez-Berestein Gabriel, Pavlov Dmitri, Bulanhagui Cecile A, Millham Robert, Comin-Anduix Begoña, Reuben James M, Seja Elisabeth, Parker Charla A, Sharma Amarnath, Glaspy John A, Gomez-Navarro Jesus Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(35): 8968-77.